Effective Dosing Protocols for Melanotan II: A Comprehensive Guide

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Melanotan II is a synthetic peptide that stimulates melanin production for tanning and may enhance sexual function. Typical dosing starts with 0.25-0.5 mg every other day for 1-2 weeks, then maintenance dosing once or twice weekly. Safety data is limited, so medical consultation

# Dosing Protocols for Melanotan II: A Comprehensive Guide

Melanotan II (MT-II) is a synthetic peptide analog of the alpha-melanocyte-stimulating hormone (α-MSH). It is primarily known for its ability to stimulate melanin production, resulting in tanning of the skin. Beyond its cosmetic applications, Melanotan II has been investigated for potential benefits such as sexual function enhancement and appetite regulation. As interest in Melanotan II grows, understanding evidence-based dosing protocols is essential for safety and effectiveness. This article provides an overview of Melanotan II dosing protocols, supported by available research, and emphasizes the importance of consulting a healthcare provider before use.

---

What is Melanotan II?

Melanotan II is a synthetic cyclic peptide developed to activate melanocortin receptors (primarily MC1R), which regulate pigmentation. Unlike natural tanning, which depends on UV exposure, MT-II can induce skin darkening independently. It was initially developed for skin cancer prevention by increasing melanin levels, which offers photoprotection.

In addition to stimulating pigmentation, Melanotan II can influence sexual arousal through the MC4 receptor, leading to off-label use for erectile dysfunction and libido enhancement. Despite its growing use, Melanotan II is not FDA-approved and remains a research chemical; hence, dosing information is derived mostly from clinical trials, anecdotal reports, and peptide research communities.

---

How Does Melanotan II Work?

Melanotan II mimics α-MSH and binds to melanocortin receptors in the skin and brain. Activation of MC1R receptors on melanocytes triggers melanin synthesis, resulting in gradual skin darkening over days to weeks. The peptide’s effect on MC3R and MC4R receptors modulates appetite and sexual function, respectively.

Because MT-II induces melanogenesis without UV light, it is considered a potential approach to reduce UV-related skin damage. However, its safety profile requires careful consideration.

---

Melanotan II Dosing Protocols

Initial Loading Phase

To achieve effective tanning, users typically begin with a loading phase to saturate melanocortin receptors:

  • Dose: 0.25 to 0.5 mg per injection
  • Frequency: Every other day (e.g., Monday, Wednesday, Friday)
  • Duration: 1 to 2 weeks
  • Starting at the lower end (0.25 mg) helps minimize side effects such as nausea, flushing, or facial tanning. The dose can be gradually increased to 0.5 mg as tolerated.

    Maintenance Phase

    After the loading phase, a maintenance dose helps sustain pigmentation:

  • Dose: 0.25 mg
  • Frequency: Once or twice weekly
  • Duration: Several weeks or months depending on desired tan maintenance
  • Some users report that dosing once weekly is sufficient to maintain color, while others prefer twice weekly for more consistent results.

    Titration and Individualization

    Dosing should be individualized based on skin type, sensitivity, and response. Fair-skinned individuals may require lower doses and slower titration to avoid adverse effects. Monitoring for side effects such as nausea, flushing, or increased blood pressure is important.

    Administration

    Melanotan II is typically reconstituted from lyophilized powder with bacteriostatic water and administered via subcutaneous injection. Common injection sites include the abdomen, thigh, or upper arm. Rotating injection sites reduces local irritation.

    ---

    Evidence and Safety Considerations

    Clinical Studies

    Clinical data on Melanotan II is limited but includes some early-phase trials:

  • A 1994 study published in Journal of Clinical Endocrinology & Metabolism showed that Melanotan II increased pigmentation significantly within 2 weeks at doses of 0.025 to 0.125 mg/kg.
  • Side effects reported included nausea, flushing, and spontaneous erections, consistent with melanocortin receptor activation.
  • Due to limited large-scale human trials, long-term safety is unclear. There have been concerns about potential risks, including melanoma promotion, although no conclusive evidence exists.

    Side Effects

    Common side effects include:

  • Nausea and vomiting
  • Facial flushing
  • Increased libido and spontaneous erections
  • Appetite suppression
  • Injection site reactions
  • Rare but serious adverse events have not been well-characterized, underscoring the need for medical supervision.

    ---

    Important Precautions and Recommendations

  • Consult a healthcare provider: Melanotan II is not FDA-approved, and self-administration carries risks.
  • Avoid UV overexposure: While MT-II induces tanning, sun protection remains critical.
  • Monitor for adverse effects: Keep track of any side effects and discontinue use if severe symptoms occur.
  • Source reliability: Only use peptides from reputable sources to reduce contamination risk.
  • Not for everyone: Pregnant or breastfeeding women, individuals with skin cancer history, or autoimmune diseases should avoid Mel